Key result
This review summarizes current recommendations for managing elevated Lp(a), the limited effects of available lipid-lowering therapies, and emerging RNA-targeted therapies in development.
Why the study?
Elevated Lp(a) is an independent ASCVD risk factor with varying screening guidelines and limited pharmacological options among currently available lipid-lowering therapies.
Design
Review
Authors
Loading...
Lp(a) measurement may refine ASCVD risk assessment; leaves open targeted therapies for genetically elevated levels.
This review summarizes current screening and management recommendations for elevated Lp(a) and highlights emerging RNA-targeted therapies that substantially reduce Lp(a) synthesis.
Alhomoud et al. (2023) conducted a review in Elevated lipoprotein(a) and atherosclerotic cardiovascular disease. Lipid-lowering and emerging therapies targeting Lp(a) was evaluated. This review summarizes current recommendations for managing elevated Lp(a), the limited effects of available lipid-lowering therapies, and emerging RNA-targeted therapies in development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: